Curated News
By: NewsRamp Editorial Staff
May 19, 2026

Quantum Genesis AI Clarifies IP Rights and Quantumzyme Relationship

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • Quantum Genesis AI clarifies IP ownership to protect competitive edge in enzyme engineering and biocatalysis.
  • Company distinguishes itself from Quantumzyme LLP, detailing IP transfers via Asset Purchase Agreement and confirmatory assignment.
  • Clear IP ownership ensures responsible innovation in enzyme engineering, potentially advancing sustainable biocatalysis for a better future.
  • CEO Naveen Kulkarni's research affiliations clarified, separating Quantum Genesis AI from independent entity Quantumzyme LLP.

Impact - Why it Matters

This clarification matters because it directly affects investor confidence and the company's credibility. By distinguishing itself from Quantumzyme LLP, Quantum Genesis AI aims to prevent misunderstandings about its intellectual property ownership and research affiliations. Investors and stakeholders rely on accurate disclosures to assess the company's value and technological assets. The clarification reinforces the company's control over critical enzyme engineering and biocatalysis technologies, which are central to its business model. Without this statement, confusion could lead to misinformed investment decisions or legal disputes over IP rights.

Summary

Quantum Genesis AI Corp. (OTC: QGAI) has issued a press release to clarify its relationship with Quantumzyme LLP, a separate entity based in Bengaluru, India, which is not a subsidiary or affiliate of the company. The clarification addresses prior press releases from November 5, 2025, and February 12, 2026, that referenced scientific publications in the enzyme engineering and biocatalysis field. These publications identified Quantumzyme LLP and reflected the affiliations of researchers at the time the research was conducted. The company emphasizes that while Quantumzyme LLP conducted certain research activities, the intellectual property and technology rights relevant to Quantum Genesis AI were transferred to the company under an Asset Purchase Agreement dated February 21, 2023, and a subsequent confirmatory assignment filed on April 29, 2026.

The press release highlights that scientific publications arising from research by CEO Naveen Kulkarni appropriately reflect his affiliations at the time of submission. However, Quantum Genesis AI believes that any research conducted by Kulkarni, whether directly or through Quantumzyme LLP, that relates to the company's core enzyme engineering and biocatalysis field and is based on the transferred technology platform, methodologies, or know-how falls within the scope of the rights transferred to the company. This assertion aims to clarify the company's ownership of relevant intellectual property and its basis for prior disclosures about scientific publications.

Quantum Genesis AI is a biotechnology company focused on next-generation technologies at the intersection of artificial intelligence, computational modeling, and scientific innovation. Its strategy includes leveraging advanced data-driven tools for research and discovery. The company maintains a commitment to transparency and responsible corporate governance. For more information, visit www.qgaicorp.com and the company's profile at www.otcmarkets.com/stock/QGAI. This clarification underscores the importance of distinguishing between Quantum Genesis AI and Quantumzyme LLP to ensure accurate understanding of intellectual property rights and research affiliations.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Quantum Genesis AI Clarifies IP Rights and Quantumzyme Relationship

blockchain registration record for this content.